A short YouTube video (shorts) featuring Robert Whitfield MD and others arguing that GLP-1 appetite-suppressing drugs are uniquely effective at modifying behavior, leading to reductions in fast-food patronage, Type 2 diabetes, and dialysis demand — with consequential shifts in investment away from fast food and dialysis sectors and regret among drug company/board executives.
No drug in history has done it this effectively. So I would say if the drug Companies knew what GLP1s.
Were are doing now, they.
Would have never let them be approved. Because you think about what they're doing and you follow the money trail, which you just have to be very plain about this. Wall street has moved money out of fast food and dialysis centers because you're going to see the. The ramifications of these drugs long term is one, a big decrease in diabetes.
Type 2, and.
Two, because of that, a big decrease.
In dialysis.
So those are two.
Huge monuments.
Right?
Right. You got a lifelong patient with dialysis or you get the money quick now and it became the number one drug sold in the world. Right.
Because for your audience, what these drugs do is they modify behavior. No drug in history has done it this effectively. So the amount of people in the line at Whataburger in Texas or McDonald's in Scottsdale has gone way down.
And you can get it through insurance.
They're just kicking themselves in board meetings all the time.
